Repros Therapeutics Inc.の研究・開発費推移

Repros Therapeutics Inc.【RPRX】業績・財務データ

市場

NASDAQ

フォロー

Repros Therapeutics Inc.【RPRX】業績・財務データ

市場

NASDAQ

損益計算書

	2020/12/31	2021/12/31	2022/12/31
Financial Royalty Assets	1,960	2,065	2,125
Intangible Royalty Assets	143	171	37
Other royalty income	19	53	75
Revenues
Provision for Other Credit Losses
Research and Development Expense
Amortization of intangible assets
General and Administrative Expense
Asset Impairment Charges
Total operating expenses, net
Operating income
Equity in losses/(earnings) of equity method investees
Interest expense
(Gains)/losses on derivative financial instruments
Losses/(gains) on equity securities
Losses/(gains) on available for sale debt securities
Interest income
Other non-operating expense, net
Total other expenses/(income), net
Consolidated net income before tax
Consolidated net income
Net income attributable to non-controlling interests
Net income attributable to Royalty Pharma plc
Earnings Per Share, Basic
Earnings Per Share, Diluted